1-bromo-4-tosyloxybutane | 110798-26-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-4-tosyloxybutane
• 英文别名: 4-Bromobutyl 4-methylbenzenesulfonate
• CAS: 110798-26-0
• 化学式: C₁₁H₁₅BrO₃S
• 分子量: 307.208
• InChiKey: WAHLNJDDAMWVHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-bromo-4-tosyloxybutane 在 sodium hydroxide 、 nickel tetraaza macrocycle 、 水 作用下， 生成 对甲苯磺酸正丁酯
  参考文献：
  名称：

  Ethylene formation in the reduction of 1,4-dihaloalkanes with a nickel(I) macrocycle

  摘要：

  DOI：

  10.1021/ja00256a075
• 作为产物：
  描述：

  4-溴-1-丁醇 、 对甲苯磺酰氯 在 吡啶 作用下， 反应 0.33h， 生成 1-bromo-4-tosyloxybutane
  参考文献：
  名称：

  [EN] PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF
  [FR] PROCEDE DE PREPARATION D'ESTERS D'ACIDES CARBOXYLIQUES A SUBSTITUTION NITROOXYALKYLE, INTERMEDIAIRES UTILISES DANS LEDIT PROCEDE ET LEUR PREPARATION

  摘要：

  本发明涉及一种制备一般式(A)化合物的过程，如描述中所述，其中R是药物的基团，R1-R12是氢或烷基基团，m、n、o、q、r和s分别是0到6之间的整数，p为0或1，X为O、S、SO、SO2、NR13或PR13或芳基、杂环芳基基团，所述过程包括将一种一般式(B)的化合物与一种一般式(C)的化合物反应，其中R为上述定义，Z为氢或从Li+、Na+、K+、Ca++、Mg++、四烷基铵、四烷基磷酸盐中选择的阳离子，R1-R12和m、n、o、p、q、r、s如上所述，Y为适当的离去基团。

  公开号：

  WO2004020385A1

文献信息

• Visible-Light-Driven C4-Selective Alkylation of Pyridinium Derivatives with Alkyl Bromides
  作者：Sungwoo Jung、Sanghoon Shin、Seongjin Park、Sungwoo Hong

  DOI：10.1021/jacs.0c04499

  日期：2020.7.1

  Reported herein is a general strategy for the photochemical cross-coupling between N-amidopyridinium salts and various alkyl bro-mides under photocatalyst-free conditions, granting facile access to various C4-alkylated pyridines. This approach exploits the intri-guing photochemical activity of electron donor-acceptor (EDA) complexes between N-amidopyridinium salts and bromide, which provides a photoactive

  本文报道了在无光催化剂条件下 N-酰氨基吡啶鎓盐和各种烷基溴之间的光化学交叉偶联的一般策略，可以轻松获得各种 C4-烷基化吡啶。这种方法利用了 N-酰氨基吡啶鎓盐和溴化物之间的电子供体 - 受体 (EDA) 复合物的有趣光化学活性，它提供了能够产生甲硅烷基自由基并驱动烷基化过程的光活性处理。在温和和无金属条件下复杂化合物的后期功能化进一步证明了该协议的稳健性。
• Light Emitting Polymer Devices Using Self-Assembled Monolayer Structures
  申请人：Gough Neil

  公开号：US20100134052A1

  公开（公告）日：2010-06-03

  A light emitting device comprising a transparent substrate; a layer of conducting material in contact with the transparent substrate; a self-assembled monolayer bonded to the layer of conducting material; one or more light emitting polymer layers in electron contact to the self-assembled monolayer; and a reflective metal layer in electron contact with the light emitting polymer layer is provided. The light emitting device provided gives enhanced performance as compared to currently available devices. Also provided is a self-assembled monolayer having the formula: R 2 -R 3 —Y where Y is a group capable of electron contact with a light emitting polymer, R 3 contains a conjugated group, and R 2 is a group capable of bonding to a conducting material.

  提供一种发光装置，包括透明衬底；与透明衬底接触的导电材料层；与导电材料层结合的自组装单分子层；与自组装单分子层电子接触的一个或多个发光聚合物层；以及与发光聚合物层电子接触的反射金属层。与当前可用设备相比，提供的发光装置具有增强的性能。同时提供具有式子R2-R3-Y的自组装单分子层，其中Y是能够与发光聚合物电子接触的基团，R3包含一个共轭基团，R2是能够与导电材料结合的基团。
• Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor
  作者：Jeffrey S. Stehouwer、Matthew S. Birnbaum、Ronald J. Voll、Michael J. Owens、Susan J. Plott、Chase H. Bourke、Michael A. Wassef、Clinton D. Kilts、Mark M. Goodman

  DOI：10.1016/j.bmc.2015.06.036

  日期：2015.8

  A series of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines were synthesized and evaluated as potential positron emission tomography (PET) tracers for the corticotropin-releasing factor type-1 (CRF1) receptor. Compounds 27, 28, 29, and 30 all displayed high binding affinity (<= 1.2 nM) to the CRF1 receptor when assessed by in vitro competition binding assays at 23 degrees C, whereas a decrease in affinity (>= 10-fold) was observed with compound 26. The logP(7.4) values of [F-18]26-[F-18] 29 were in the range of similar to 2.2-2.8 and microPET evaluation of [F-18]26-[F-18] 29 in an anesthetized male cynomolgus monkey demonstrated brain penetrance, but specific binding was not sufficient enough to differentiate regions of high CRF1 receptor density from regions of low CRF1 receptor density. Radioactivity uptake in the skull, and sphenoid bone and/or sphenoid sinus during studies with [F-18]28, [F-18]28-d(8), and [F-18]29 was attributed to a combination of [F-18]fluoride generated by metabolic defluorination of the radiotracer and binding of intact radiotracer to CRF1 receptors expressed on mast cells in the bone marrow. Uptake of [F-18]26 and [F-18]27 in the skull and sphenoid region was rapid but then steadily washed out which suggests that this behavior was the result of binding to CRF1 receptors expressed on mast cells in the bone marrow with no contribution from [F-18]fluoride. (C) 2015 Elsevier Ltd. All rights reserved.
• [EN] PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF<br/>[FR] PROCEDE DE PREPARATION D'ESTERS D'ACIDES CARBOXYLIQUES A SUBSTITUTION NITROOXYALKYLE, INTERMEDIAIRES UTILISES DANS LEDIT PROCEDE ET LEUR PREPARATION
  申请人：NICOX SA

  公开号：WO2004020385A1

  公开（公告）日：2004-03-11

  The present invention refers to a process for preparing a compound of general formula (A), as reported in the description, wherein R is a radical of a drug and R1-R12 are hydrogen or alkyl groups, m, n, o, q, r and s are each independently an integer from 0 to 6, and p is 0 or 1, and X is O, S, SO, SO2, NR13 or PR13 or an aryl, heteroaryl group, said process comprising reacting a compound of formula (B) R-COOZ (B) wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1-R12 and m, n, o, p, q, r, s are as defined above and Y is a suitable leaving group.

  本发明涉及一种制备一般式(A)化合物的过程，如描述中所述，其中R是药物的基团，R1-R12是氢或烷基基团，m、n、o、q、r和s分别是0到6之间的整数，p为0或1，X为O、S、SO、SO2、NR13或PR13或芳基、杂环芳基基团，所述过程包括将一种一般式(B)的化合物与一种一般式(C)的化合物反应，其中R为上述定义，Z为氢或从Li+、Na+、K+、Ca++、Mg++、四烷基铵、四烷基磷酸盐中选择的阳离子，R1-R12和m、n、o、p、q、r、s如上所述，Y为适当的离去基团。
• Ethylene formation in the reduction of 1,4-dihaloalkanes with a nickel(I) macrocycle
  作者：James H. Espenson、M. S. Ram、Andreja Bakac

  DOI：10.1021/ja00256a075

  日期：1987.10